

## Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Follicular, Mantle Cell and Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements best characterizes observations of cytokine release syndrome (CRS) with lisocabtagene maraleucel in the Phase II TRANSCEND FL trial for patients with relapsed/refractory follicular lymphoma (FL)?
  - a. CRS was not observed
  - b. Most events were Grade 1 to 2
  - c. Most events were Grade 3
  - d. Most events were Grade 4
2. What proportion of patients experienced an objective response in a Phase Ib study of acalabrutinib/venetoclax/rituximab for treatment-naïve mantle cell lymphoma?
  - a. 25%
  - b. 33%
  - c. 50%
  - d. 100%
3. Which of the following outcomes was observed from long-term follow-up of the Phase III GALLIUM trial evaluating the combination of obinutuzumab/chemotherapy compared to rituximab/chemotherapy for patients with previously untreated FL?
  - a. Improved overall survival (OS) with obinutuzumab/chemotherapy
  - b. Improved progression-free survival (PFS) with obinutuzumab/chemotherapy
  - c. No improvement in OS or PFS with obinutuzumab/chemotherapy
4. Which of the following adverse events was more commonly reported among patients receiving R<sup>2</sup> compared to R-chemo for advanced untreated FL in the Phase III RELEVANCE trial?
  - a. Rash
  - b. Neuropathy
  - c. Alopecia
  - d. Anemia
5. Which of the following proteins is targeted by zimberelimab?
  - a. CD30
  - b. LAG-3
  - c. PD-1
  - d. HER2